Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia. Participants: Up to 80 adults with schizophrenia for at least one year and with a high rating for paranoia. Procedures (methods): Oxytocin or placebo will be administered twice daily in an intranasal spray (6 insufflations/dose or 24 IU) for 6 weeks. Before, during and at the end of the trial, each subject will undergo social cognitive measures (primary outcomes) and psychiatric symptom ratings (secondary outcomes).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Emotion Recognition as Measured by the Emotion Recognition-40 at the 6 Week Time Point
Timeframe: 6 weeks
Theory of Mind as Measured by the Eyes Test at 6 Weeks
Timeframe: 6 weeks
Theory of Mind as Measured by the Brune Test at 6 Weeks
Timeframe: 6 weeks
Social Perception as Measured by the Trustworthiness Task at 6 Weeks
Timeframe: 6 weeks
Empathy as Measured by the Interpersonal Reactivity Index (IRI) at 6 Weeks
Timeframe: 6 weeks